IDH1-mutant metabolite D-2-hydroxyglutarate inhibits proliferation and sensitizes glioma to temozolomide via down-regulating ITGB4/PI3K/AKT.
Cell death discovery
Tong S, Wu J, Song Y, Fu W, Yuan Y, Zhong P, Liu Y, Wang B.
Publication Overview
Key findings, Countstar context, and access to the original paper.
2024
Cancer Research
No items found.
Key Finding
Finally, by integrating data from the CGGA and TCGA databases, it was validated that ITGB4 expression was lower in IDH1-mutant gliomas, and patients with lower ITGB4 expression were associated with better prognosis. These findings indicate that ITGB4 may be a promising therapeutic target for gliomas and D-2HG inhibits proliferation and sensitizes glioma to temozolomide via down-regulating ITGB4/PI3K/AKT.
Countstar Connection
The study measured cell numbers in the study's cell samples using a Countstar instrument during growth assessment for the cancer-model experiments.
